Clinical trials: Hepatobiliary Disease
NASH - Nonalcoholic Steatohepatitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Trial name
- NCT04054310
- Testing
- Liver Multi Scan
- Where
- 7 sites in United States
- Volunteers
- 225 people
- Sponsor
- Perspectum
Type 2 Diabetes, Obesity
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).
- Conditions
- Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07570810
- Testing
- CS0159, Semaglutide
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non Alcoholic Fatty Liver Disease
Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)
A research study of a compound containing vitamin E, silymarin and carnitine, three over the counter supplements. The investigators hope to learn if the new supplement can safely and successfully treat fatty liver disease or Non…
- Trial name
- NCT01511523
- Testing
- RGMA001, Sugar Pill
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Biovil Research Group, LLC
MASH, NASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression…
- Conditions
- MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis
- Trial name
- FASCINATE-3 (NCT06594523)
- Testing
- Denifanstat
- Sponsor
- Sagimet Biosciences Inc.
Non-Alcoholic Fatty Liver Disease
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT06717828
- Testing
- Tai Chi Exercise, Regular Exercise, Control
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Provincial Hospital
NAFLD
Defining Circadian Metabolism in Non-alcoholic Fatty Liver Disease
The investigators will conduct an open label, experimental medicine study exploring the diurnal patterns of hepatic lipid metabolism in NAFLD and non-NAFLD participants (determined by Transient elastography (TE) with controlled…
- Trial name
- DECIMAL (NCT05962099)
- Testing
- Lifestyle and weight loss advice
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Oxford
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes
Alcohol-related Liver Disease, Alcohol Use Disorder
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
Excessive alcohol use is a leading risk factor for preventable disability and death. Alcohol-related liver disease (ALD) is one of the better-known detrimental consequences of alcohol abuse and is the main cause of…
- Conditions
- Alcohol-related Liver Disease, Alcohol Use Disorder, Metabolic and Alcohol Related/Associated Liver Disease, Metabolic Disfunction Associated Steatotic Liver Disease
- Trial name
- StopALD (NCT06403332)
- Testing
- brief intervention
- Where
- 2 sites in Spain
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatitis
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance.
- Trial name
- NCT00063232
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
NAFLD Primary Care
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Type2 Diabetes, Metabolic Syndrome
- Trial name
- NCT04918732
- Testing
- FibroScan
- Where
- Netherlands
- Volunteers
- 1,470 people
- Sponsor
- Maastricht University
X-Linked Myotubular Myopathy
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness.
- Trial name
- EXCEL (NCT06581146)
- Testing
- No Intervention
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 50 people
- Sponsor
- Astellas Gene Therapies
Liver Fibrosis, NASH
Early Liver Disease Breath Detection
The Early Liver Disease Breath Detection Study is a cross-sectional study where subjects with advanced liver fibrosis will ingest a mixture of food-grade compounds (known as Exogenous Volatile Organic Compound or EVOCs) in the…
- Conditions
- Liver Fibrosis, NASH, Liver Diseases
- Trial name
- NCT05935488
- Testing
- EVOCs emulsion
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Owlstone Ltd
Hepatobiliary Disease, Pancreas Disease
Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries
Hepatobiliary and Pancreatic surgery is associated with substantial risk of postoperative complications. Albumin is a negative acute phase protein.
- Conditions
- Hepatobiliary Disease, Pancreas Disease, Bile Duct Diseases
- Trial name
- NCT07263061
- Testing
- NO TREATMENT
- Where
- India
- Volunteers
- 1,000 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Diseases
Effect of Lockdown During COVID 19 Pandemic on Liver Disease and Metabolic Parameters.
The novel corona virus disease (COVID-19), pandemic has costed lives of several hundred thousands and affected millions. Comorbidities such as metabolic syndrome components and chronic liver disease have been associated with more…
- Trial name
- NCT05028842
- Testing
- No intervention
- Where
- India
- Volunteers
- 230 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Polycystic Liver Disease, Hepatomegaly
Open-Label Extension of LOCKCYST Trial
Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney
- Trial name
- LOCKCYST-ext (NCT00771888)
- Testing
- lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 54 people
- Sponsor
- Radboud University Medical Center
Hepatic Impairment
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired hepatic function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg…
- Trial name
- NCT01767103
- Testing
- Ferriprox®
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- ApoPharma
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI > 25)
- Trial name
- NCT07193927
- Testing
- Lactiplantibacillus plantarum Probiotic Mixture
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- AB Biotics, SA
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
A Phase 2 study with 4 treatment groups of two differing doses and matched placebos designed to evaluate the safety (including hepatic safety), tolerability and pharmacodynamic effects of two dose levels of MEDI0382 in obese…
- Trial name
- NCT04019561
- Testing
- MEDI0382 high dose, MEDI0382 low dose
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- MedImmune LLC
Alcoholism, Alcohol Abuse
Health Behavior Feedback Study for Veterans With Hepatitis C
The purpose of this study was to explore whether a brief (3 session) intervention would impact health behavior of veterans with hepatitis C.
- Conditions
- Alcoholism, Alcohol Abuse, Hepatitis C, Liver Disease
- Trial name
- NCT00229580
- Testing
- 3 session brief intervention with health behavior feedback, treatment as usual
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Chronic Hepatitis B, Hepatic Fibrosis
Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD
Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C.
- Conditions
- Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
- Trial name
- NCT02031913
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital